Treatment options for hepatic encephalopathy: A review

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 2, 2007, Pages 10-17

  Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Branched chain amino acids; Hepatic encephalopathy; L ornithine L aspartate; Lactulose; Neomycin

Indexed keywords

AMMONIA; ANTIBIOTIC AGENT; AROMATIC AMINO ACID; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; DISACCHARIDE; ENEMA; FLUMAZENIL; LACTITOL; LACTULOSE; LEVODOPA; METRONIDAZOLE; NARCOTIC AGENT; NEOMYCIN; ORNITHINE ASPARTATE; PROBIOTIC AGENT; RIFAXIMIN; SEDATIVE AGENT; THIAMINE; TRANQUILIZER; VANCOMYCIN; ZINC;

ABDOMINAL CRAMP; BACTERIAL OVERGROWTH; BRAIN EDEMA; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DIET THERAPY; DRUG DOSE TITRATION; ELECTROLYTE DISTURBANCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; META ANALYSIS; METABOLIC ACIDOSIS; NEPHROTOXICITY; OTOTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DIET; REVIEW; RISK FACTOR; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34548177698     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984574     Document Type: Review

References (53)

1. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-2304
2. Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007;22:125-138
3. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-773
4. Conn H, Lieberthal MM. Hepatic Coma Syndromes and Lactulose. Baltimore: Lippincott Williams & Wilkins; 1979
5. Ferenci P, Muller CH. Hepatic encephalopathy: treatment. In: Burroughs AK, Feagan B, McDonald JE, eds. Evidence Based Gastroenterology. London: BMJ; 1999:443
6. Fessel JM, Conn HO. An analysis of the causes and prevention of hepatic coma. Gastroenterology 1972;62:191 (Abstract)
7. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-643
8. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997;16:43-55
9. Riggio O, Varriale M, Testore GP, et al. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. J Clin Gastroenterol 1990;12:433-436
10. Mortensen PB. The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 1992;16:1350-1356
11. Mortensen PB, Holtug K, Bonnen H, Clausen MR. The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology 1990;98:353-360
12. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology 1977;72:573-583
13. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046
14. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987;7:1278-1284
15. Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992;15:222-228
16. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy: a meta-analysis. Dig Dis Sci 1993;38:916-922
17. Uribe-Esquivel M, Moran S, Poo JL, Munoz RM. In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters. Scand J Gastroenterol Suppl 1997;222:49-52
18. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-545
19. Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990;31:702-706
20. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005;46:399-407
21. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208
22. Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 2005;51(suppl 1):90-95
23. Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006;73(suppl 1):94-101
24. Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):23-31
25. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis: a double-blind, randomized study using a four-fold crossover design. J Hepatol 1993;19:424-430
26. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351-1360
27. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-864
28. Fleig WE, Kircheis G, Spengler U, et al. Placebo-controlled, double-blind evaluation of L-ornithine-L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild or overt hepatic encephalopathy [abstract]. J Hepatol 1999;31(suppl 2):WP3/1
29. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992;16:138-144
30. Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 2000;95:3574-3578
31. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38-43
32. Nielsen K, Kondrup J, Martinsen L, Stilling B, Wikman B. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. Br J Nutr 1993;69:665-679
33. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy: a randomized cross-over comparison. J Intern Med 1993;233:385-392
34. Ferenci P. Critical evaluation of the role of branched chain amino acids in liver disease. In: Thomas HC, Jones EA, eds. Recent Advances in Hepatology. Vol. 2. New York: Churchill Livingstone; 1986:137
35. Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy: a meta-analysis. Gastroenterology 1989;97:1033-1042
36. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003;(2):CD001939
37. Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy: a randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990;11:92-101
38. Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984;4:279-287
39. Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991;325:473-478
40. Barbara G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-378
41. Cadranel JF, el Younsi M, Pidoux B, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 1995;7:325-329
42. Gyr K, Meier R, Haussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996;39:319-324
43. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994;19:32-37
44. Van der Rijt CC, Schalm SW, Meulstee J, Stijnen T. Flumazenil therapy for hepatic encephalopathy: a double-blind cross over study. Gastroenterol Clin Biol 1995;19:572-580
45. Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001;(2):CD002798
46. Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002;16:361-372
47. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-1092
48. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-1118
49. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-1208
50. Blanc P, Daures JP, Liautard J, et al. [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy: results of a randomized controlled trial]. Gastroenterol Clin Biol 1994;18:1063-1068
51. Wahren J, Denis J, Desurmont P, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 1983;3:475-480
52. Michel H, Pomier-Layrargues G, Aubin JP, et al. Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a study in 47 cirrhotic patients. In: Capocaccia L, Fischer J, Rossi-Fanelli F, eds. Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press; 1984:301-310
53. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721